ProCE Banner Activity

Equitable Care Delivery in Gynecologic Cancers: Patient and HCP Survey Results

Clinical Thought

Shannon N. Westin, MD, MPH, shares her takeaways from a patient preference survey administered to patients with gynecologic cancers covering topics such as cancer biomarkers guiding therapy and equitable delivery of gynecologic cancer care.

Released: March 08, 2023

Share

Faculty

Shannon N. Westin

Shannon N. Westin, MD, MPH, FASCO

Professor
Medical Director, Gynecologic
Oncology Center
Division of Surgery
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

ProCE Banner

Supporters

Supported by educational grants from

Eisai

GSK

Karyopharm Therapeutics Inc.

Merck Sharp & Dohme, LLC

Seagen and Genmab

Partners

Smart Patients

ProCE Banner

Disclosure

Shannon N. Westin, MD, MPH: consultant/advisor/speaker: AstraZeneca, Caris, Clovis, Eisai, EQRX, Genentech/Roche, GlaxoSmithKline, ImmunoGen, Lilly, Merck, Mereo, Mersana, NGM Bio, Nuvectis, Seagen, Verastem, Vincerx, Zentalis; researcher: AstraZeneca, AvengeBio, Bayer, Bio-Path, Clovis, Genentech/Roche, GlaxoSmithKline, Mereo, Novartis, Zentalis.